The round was led by Nikon with participation from existing investors Sequoia Capital, Walden-Riverwood Ventures, Black Diamond Ventures, and Paxion Capital; and joined by new investors Cota Capital, KTB Network, Atinum Investment, Shangbay Capital, AJS BioTree Healthcare Fund, and Varian.
The company intends to use the funds to expedite solutions for cell therapy development and manufacturing, including CAR T and endogenous T-cells, as well as increase research and development and expansion of commercial activities.
Led by Eric Hobbs, Ph.D., CEO, Berkeley Lights has developed nanoscale technology that accelerates drug discovery and development processes through the combination of bioscience, technology, and information. The platform uses optofluidic light technology to individually isolate, culture, perform assays and export thousands of live cells in conjunction with visual and digital monitoring. The digital and analytical insights provided allows scientists to make informed decisions, so they can select and retrieve the best cells, leading to more consistent production of therapeutics in a reduced timeframe.
The digital cell biology platform is used by biopharmaceutical companies working in large molecule drug discovery and development.
FinSMEs
15/10/2018